| Returns | 1W : -3.2% , 1M : 8.7%,1Y : 100.1% |
| Peers & Returns | 1W | 1M | 1Y |
| GUFIC BIOSCIENCES LTD | -3.2% | 8.7% | 100.1% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -2.1% | 7.7% | 32.6% |
| DR REDDYS LABORATORIES LTD | -4.4% | 0.3% | 66.4% |
| DIVIS LABORATORIES LTD | -3.2% | -0.7% | 90.1% |
| CIPLA LTD | -0.9% | 7% | 71.3% |
| BIOCON LTD | -3.7% | -0.2% | 54.7% |
| AUROBINDO PHARMA LTD | -3.1% | 10% | 91.3% |
| LUPIN LTD | -1.7% | 16.9% | 48.8% |
| TORRENT PHARMACEUTICALS LTD | -2.4% | 2.1% | 35.6% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
41.45
P/E Calculated based on EPS of 2.94
[ Mar2020 - Standalone Results ] 9.89
P/B Calculated based on Book Value of 12.32
[ Mar2020 - Standalone Results ] 2.97
P/S Calculated based on Revenues of 319.504 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
60% 86% 96% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
1.16 1.3 1.47 1.31 |
- - - - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
122.27% 6939.39% -530.58% -535.7% |
39.9% 136.2% 289.44% 279.5% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
